Literature DB >> 12815157

Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors.

Uta Voigtländer1, Kirstin Jöhren, Marion Mohr, Alexandra Raasch, Christian Tränkle, Stefan Buller, John Ellis, Hans-Dieter Höltje, Klaus Mohr.   

Abstract

Two epitopes have been identified recently to be responsible for the high-affinity binding of alkane-bisammonium and caracurine V type allosteric ligands to N-methylscopolamine (NMS)-occupied M2 muscarinic acetylcholine receptors, relative to M5 receptors: the amino acid M2-Thr423 at the top of transmembrane region (TM) 7 and an epitope comprising the second extracellular loop (o2) of the M2 receptor including the flanking regions of TM4 and TM5. We aimed to find out whether a single amino acid could account for the contribution of this epitope to binding affinity. Allosteric interactions were investigated in wild-type and mutant receptors in which the orthosteric binding site was occupied by [3H]NMS (5 mM Na,K,Pi buffer, pH 7.4, 23 degrees C). Using M2/M5 chimeric and point-mutated receptors, the relevant epitope was narrowed down to M2-Tyr177. A double point-mutated M2 receptor in which both M2-Tyr177 and M2-Thr423 were replaced by the corresponding amino acids of M5 revealed that these two amino acids account entirely for the (approximately 100-fold) M2/M5 selectivity of the alkane-bisammonium and the caracurine V type allosteric ligands. At NMS-free M2 receptors, the caracurine V derivative also displayed approximately 100-fold M2/M5 selectivity, but the double point mutation reduced the M2 affinity by only approximately 10-fold; thus, additional epitopes may influence selectivity for the free receptors. A three-dimensional model of the M2 receptor was used to simulate allosteric agent docking to NMS-occupied receptors. M2-Tyr177 and M2-Thr423 seem to be located near the junction of the allosteric and the orthosteric areas of the M2 receptor ligand binding cavity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815157     DOI: 10.1124/mol.64.1.21

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  28 in total

1.  Molecular dynamics simulations of bovine rhodopsin: influence of protonation states and different membrane-mimicking environments.

Authors:  Birgit Schlegel; Wolfgang Sippl; Hans-Dieter Höltje
Journal:  J Mol Model       Date:  2005-10-25       Impact factor: 1.810

2.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs.

Authors:  Ron O Dror; Hillary F Green; Celine Valant; David W Borhani; James R Valcourt; Albert C Pan; Daniel H Arlow; Meritxell Canals; J Robert Lane; Raphaël Rahmani; Jonathan B Baell; Patrick M Sexton; Arthur Christopoulos; David E Shaw
Journal:  Nature       Date:  2013-10-13       Impact factor: 49.962

3.  The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers.

Authors:  Dylan P Kennedy; Fiona M McRobb; Susan A Leonhardt; Michael Purdy; Heidi Figler; Melissa A Marshall; Mahendra Chordia; Robert Figler; Joel Linden; Ruben Abagyan; Mark Yeager
Journal:  Mol Pharmacol       Date:  2013-11-11       Impact factor: 4.436

4.  Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.

Authors:  Maren Grossmüller; Johannes Antony; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-16       Impact factor: 3.000

5.  Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.

Authors:  Karen J Gregory; Nathan E Hall; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

Review 6.  Rational design of dualsteric GPCR ligands: quests and promise.

Authors:  Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

7.  Novel allosteric effects of amiodarone at the muscarinic M5 receptor.

Authors:  Edward Stahl; John Ellis
Journal:  J Pharmacol Exp Ther       Date:  2010-03-26       Impact factor: 4.030

Review 8.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

9.  A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization.

Authors:  Eelke van der Horst; Julio E Peironcely; Adriaan P Ijzerman; Margot W Beukers; Jonathan R Lane; Herman W T van Vlijmen; Michael T M Emmerich; Yasushi Okuno; Andreas Bender
Journal:  BMC Bioinformatics       Date:  2010-06-10       Impact factor: 3.169

10.  Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

Authors:  Katie Leach; Richard E Loiacono; Christian C Felder; David L McKinzie; Adrian Mogg; David B Shaw; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropsychopharmacology       Date:  2009-11-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.